Efficacy of peg-interferon-α-2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea

Background and Aim:  In the present study, we evaluated the safety and efficacy of combination therapy with pegylated interferon and ribavirin for treating chronic hepatitis C (CHC) patients aged 60 years and older. Methods:  A total of 314 CHC patients, who were treated with combination therapy, we...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2011-03, Vol.26 (3), p.469-476
Main Authors: Sinn, Dong Hyun, Shin, Su Rin, Kil, Jae Sook, Kim, Jeong, Gwak, Geum-Youn, Choi, Moon Seok, Lee, Joon Hyeok, Koh, Kwang Cheol, Yoo, Byung Chul, Paik, Seung Woon
Format: Article
Language:English
Subjects:
Age Factors
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Asian Continental Ancestry Group
Aspartate Aminotransferases - blood
aspartate aminotransferase : platelet ratio index
Biological and medical sciences
Biomarkers - blood
Chi-Square Distribution
elderly patient
Female
Gastroenterology. Liver. Pancreas. Abdomen
Hepacivirus - genetics
hepatitis C virus
hepatitis C virus
pegylated interferon
Hepatitis C, Chronic - diagnosis
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - ethnology
Human viral diseases
Humans
Infectious diseases
Interferon-alpha - adverse effects
Interferon-alpha - therapeutic use
Korea
Logistic Models
Male
Medical sciences
Middle Aged
Odds Ratio
Patient Selection
pegylated interferon
Pharmacology. Drug treatments
Polyethylene Glycols - adverse effects
Polyethylene Glycols - therapeutic use
Recombinant Proteins
Retrospective Studies
ribavirin
Ribavirin - adverse effects
Ribavirin - therapeutic use
Risk Assessment
Risk Factors
RNA, Viral - blood
Time Factors
Treatment Outcome
Viral diseases
Viral hepatitis
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim:  In the present study, we evaluated the safety and efficacy of combination therapy with pegylated interferon and ribavirin for treating chronic hepatitis C (CHC) patients aged 60 years and older. Methods:  A total of 314 CHC patients, who were treated with combination therapy, were classified into three groups according to age: (i) younger than 50 years (n = 137); (ii) 50–59 years (n = 109); and (iii) 60 years or older (n = 68). The sustained virological response (SVR) and discontinuation rates were compared between the three groups. Results:  Discontinuation of therapy due to adverse event was more frequent in the older patient groups: 1%, 5%, and 10% for the
ISSN:0815-9319
1440-1746
DOI:10.1111/j.1440-1746.2010.06478.x